William Blair & Company
TERN

William Blair & Company’s Terns Pharmaceuticals TERN Stock Holding History

William Blair & Company’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$419K Buy
7,947
+1,897
+31% +$77.9K ﹤0.01% 1208
2025
Q4 		$244K Buy
+6,050
New +$140K ﹤0.01% 1385

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

William Blair & Company's TERN Position: Q1 2026 in Review

William Blair & Company increased its Terns Pharmaceuticals (TERN) stake by 31% in Q1 2026, buying an estimated $77.9K and bringing the position to 7,947 shares worth $419K. The position accounts for ﹤0.01% of the portfolio, ranked #1208.

William Blair & Company first reported a position in TERN in Q4 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • William Blair & Company held 7,947 shares of Terns Pharmaceuticals worth $419K as of Q1 2026.
  • William Blair & Company bought 1,897 Terns Pharmaceuticals shares in Q1 2026, an estimated $77.9K.
  • Terns Pharmaceuticals made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1208 holding.
  • William Blair & Company first reported a position in Terns Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.